Triple
T7392984
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | George Church |
E170546
|
entity |
| Predicate | coFounded |
P104
|
FINISHED |
| Object |
Editas Medicine
Editas Medicine is a biotechnology company focused on developing CRISPR-based gene-editing therapies to treat serious genetic diseases.
|
E661988
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Editas Medicine | Statement: [George Church, coFounded, Editas Medicine]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Editas Medicine Context triple: [George Church, coFounded, Editas Medicine]
-
A.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
B.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
-
C.
Juno Therapeutics
Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
-
D.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
E.
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Editas Medicine Triple: [George Church, coFounded, Editas Medicine]
Generated description
Editas Medicine is a biotechnology company focused on developing CRISPR-based gene-editing therapies to treat serious genetic diseases.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Editas Medicine Target entity description: Editas Medicine is a biotechnology company focused on developing CRISPR-based gene-editing therapies to treat serious genetic diseases.
-
A.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
B.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi)-based therapeutics for genetically defined diseases.
-
C.
Juno Therapeutics
Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
-
D.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
E.
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c68a5e2c9081909e713ce866e0060a |
completed | March 27, 2026, 1:47 p.m. |
| NER | Named-entity recognition | batch_69c6f224790c819099ceb7c7ac8d00f6 |
completed | March 27, 2026, 9:09 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c810f82ba08190919924b0994a2eee |
completed | March 28, 2026, 5:33 p.m. |
| NEDg | Description generation | batch_69c811f1fe3c8190a591186b19044b5f |
completed | March 28, 2026, 5:37 p.m. |
| NED2 | Entity disambiguation (via description) | batch_69c812c1e9d08190b0e7f052d87011b9 |
completed | March 28, 2026, 5:41 p.m. |
Created at: March 27, 2026, 3:09 p.m.